News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 21, 2024

Examining Key Unmet Needs in Multiple Sclerosis

Author(s)Ryan Haumschild, PharmD, MS, MBA, Heidi Crayton, MD , Maria Lopes, MD

Key opinion leaders discuss the most significant unmet needs in the current treatment landscape for multiple sclerosis.

Episodes in this series

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

Video 1 - 3 KOLs are featured in, "Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression"

EP. 2 Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

Video 2 - 3 KOLs are featured in, "Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis"

EP. 3 Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

3 KOLs in this program

EP. 4 Examining Key Unmet Needs in Multiple Sclerosis

3 KOLs in this program

EP. 5 Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 6 MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

A panel of 3 experts on multiple sclerosis

EP. 7 Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 8 Examining Challenges with Drug Switching and Step Therapy in MS Treatment

A panel of 3 experts on multiple sclerosis

EP. 9 Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 10 BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 11 Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

A panel of 3 experts on multiple sclerosis

EP. 12 Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

A panel of 3 experts on multiple sclerosis

EP. 13 Multiple Sclerosis: Looking Toward the Future

What do you view as the biggest unmet needs in the current treatment landscape for MS?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dexamethasone Before R-CHOP in DLBCL With GI Involvement Can Limit Complications, Retain Efficacy

January 25th 2026

Doctor conducting liquid biopsy | Image Credit: syhin_stas - stock.adobe.com

ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC

ByBrooke McCormick

January 25th 2026

First-line anlotinib plus chemotherapy demonstrates favorable efficacy and manageable toxicity in advanced STS. | Image credit: @Aidman-Adobestock.jpeg

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

BySabrina McCrear

January 23rd 2026

Mitzi Wasik, PharmD, MBA, BCPS, FAMCP, FCCP, executive director of the AMCP Foundation and senior vice president of Practice Strategy and Innovation at AMCP | Image credit: AMCP

RWD Is Transforming Mental Health, Neurology Managed Care: Mitzi Wasik, PharmD

ByRose McNulty,Mitzi Wasik, PharmD, MBA

January 22nd 2026

computer-generated lungs | Image Credit: Rasi - stock.adobe.com

Oral Nalbuphine Significantly Reduces Chronic Cough in IPF

BySabrina McCrear

January 22nd 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Trending on AJMC

Congress Unveils Massive Funding Bill to Avert Shutdown

Novel CLL Therapies Prompt New Treatment Considerations

ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC

Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma

Health Insurance CEOs Questioned by House Committee About Rising Costs in Health Care

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.